Hologic Inc (HOLX) Stock Price, Quote & News

Company Profile

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, an...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 508 263 2900

Website: www.hologic.com

Address:

250 Campus Drive, Marlborough, United States

ZacksResearch Sep. 10 at 3:09 PM

$HOLX raises fiscal 2025 guidance amid strategic moves! 📈 👍 Breast Health rebound expected with strategic leadership changes and innovation. 💰 Tariff costs reduced through supply chain adjustments. 🌍 GYN Surgical sees 24.8% international growth in Q3, setting up a strong Q4. See how analysts are projecting Hologic’s future earnings 👉 https://www.zacks.com/stock/news/2749406/hologics-2025-outlook-improves-on-strong-q3-easing-tariff-headwinds?cid=sm-stocktwits-2-2749406-body-11750&ADID=SYND_STOCKTWITS_TWEET_2_2749406_BODY_11750

0 · Reply

ZacksResearch Sep. 10 at 2:09 PM

$HOLX just turned a corner 🚀 Q3 strength and easing tariff headwinds have lifted the company’s 2025 outlook — a clear momentum shift. Full breakdown of the improved setup here 👉 https://www.zacks.com/stock/news/2749406/hologics-2025-outlook-improves-on-strong-q3-easing-tariff-headwinds?cid=sm-stocktwits-2-2749406-teaser-11700&ADID=SYND_STOCKTWITS_TWEET_2_2749406_TEASER_11700

0 · Reply

Knot2 Sep. 5 at 8:18 PM

$KVUE $HOLX curtain being rolled back. $NVDA $QQQ $$OPEN

0 · Reply

StockAutoPro Sep. 5 at 7:50 PM

$HOLX: Buy target $64.55 Sell target $69.88 Expect potential growth in the medical technology sector due to increased healthcare demand.

0 · Reply

Knot2 Sep. 4 at 6:21 PM

$HOLX this company and its relationship with prior FDA… makes RFK look sane $QQQ $OPEN $NVDA

1 · Reply

ZacksResearch Sep. 4 at 2:10 PM

$HOLX's Panther platform remains foundational — but is the stock undervalued? 🤔 📈 Shares up 6.7% in six months, bucking the industry's 11.2% decline 💡 Trading at a forward P/E of 14.84X vs. industry avg of 28.05X ⚙️ Expanding its assay menu and driving growth in molecular diagnostics See if HOLX’s growth potential justifies its valuation here 👉 https://www.zacks.com/stock/news/2747090/hologics-panther-fusion-signals-more-molecular-diagnostics-upside?cid=sm-stocktwits-2-2747090-body-10884&ADID=SYND_STOCKTWITS_TWEET_2_2747090_BODY_10884

0 · Reply

ZacksResearch Sep. 4 at 12:42 PM

$HOLX showing more fuel in the tank? 🚀 Panther Fusion is spotlighting added momentum for the company’s molecular diagnostics segment — signaling more upside potential ahead. Full breakdown here 👉 https://www.zacks.com/stock/news/2747090/hologics-panther-fusion-signals-more-molecular-diagnostics-upside?cid=sm-stocktwits-2-2747090-teaser-10861&ADID=SYND_STOCKTWITS_TWEET_2_2747090_TEASER_10861

0 · Reply

StockAutoPro Sep. 4 at 5:03 AM

$HOLX: Buy target $64.24 Sell target $69.55 Significant growth in women's health segment suggests potential investment opportunity in this medical technology company.

0 · Reply

Knot2 Sep. 3 at 10:34 PM

$HOLX Is the Biozorb fiasco in the price of HOLX? 97% institutional holders Should be a RICO case Stuff that makes RFK look sane

0 · Reply

StockAutoPro Aug. 29 at 5:02 PM

$HOLX: Buy target $64.69 Sell target $70.02 Consider buying as company shows strong growth in medical imaging and diagnostics sector.

0 · Reply

Hologic, Inc. (HOLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 4:02 PM EDT - 9 days ago

Hologic to Webcast Presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference

Jul 30, 2025, 7:12 PM EDT - 6 weeks ago

Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript

Jul 30, 2025, 6:06 PM EDT - 6 weeks ago

Hologic raises annual profit forecast on diagnostic and surgical demand

Jul 30, 2025, 4:01 PM EDT - 6 weeks ago

Hologic Announces Financial Results for Third Quarter of Fiscal 2025

Jul 22, 2025, 5:06 PM EDT - 7 weeks ago

Hologic Q3 Preview: Tariff Pressure And Undervalued Stock Price, Initiate With Buy

Jul 2, 2025, 4:05 PM EDT - 2 months ago

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025

Jun 2, 2025, 11:03 AM EDT - 3 months ago

Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation

May 27, 2025, 3:48 PM EDT - 3 months ago

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?

May 27, 2025, 1:05 PM EDT - 3 months ago

Hologic rejects $16 billion take-private proposal from TPG and Blackstone, Financial Times reports

BX TPG

May 22, 2025, 5:05 PM EDT - 4 months ago

Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients

May 13, 2025, 4:10 PM EDT - 4 months ago

Hologic to Webcast Presentations at Upcoming Investor Conferences

May 6, 2025, 5:39 PM EDT - 4 months ago

Hologic: Soft Performance, But Cheap Enough

May 1, 2025, 8:24 PM EDT - 4 months ago

Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript

May 1, 2025, 6:58 PM EDT - 4 months ago

Medical equipment maker Hologic lowers annual profit forecast on tariff uncertainty

May 1, 2025, 4:01 PM EDT - 4 months ago

Hologic Announces Financial Results for Second Quarter of Fiscal 2025

Apr 25, 2025, 4:25 AM EDT - 5 months ago

Cellulite Treatment Market Trends, Growth Opportunities and Shares 2025-2030; Featuring Key Players - Hologic (Cynosure), Merz Pharma, Syneron Medical, Zimmer Aesthetics & More

Apr 24, 2025, 8:10 AM EDT - 5 months ago

Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI

Apr 22, 2025, 8:08 AM EDT - 5 months ago

Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report

Apr 4, 2025, 4:15 PM EDT - 5 months ago

Wayde McMillan Elected to Hologic Board of Directors

Apr 3, 2025, 4:30 PM EDT - 5 months ago

Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025

Feb 25, 2025, 8:15 AM EST - 7 months ago

Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference

Feb 20, 2025, 3:00 AM EST - 7 months ago

Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software

Feb 18, 2025, 8:08 AM EST - 7 months ago

Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay

Feb 5, 2025, 10:06 PM EST - 7 months ago

Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript

Feb 5, 2025, 5:56 PM EST - 7 months ago

Hologic cuts annual revenue forecast on weak demand for breast health products

Feb 5, 2025, 4:01 PM EST - 7 months ago

Hologic Announces Financial Results for First Quarter of Fiscal 2025

Jan 21, 2025, 8:00 AM EST - 8 months ago

New Report Reveals Alarming Decline in Women's Cancer Testing Worldwide

Jan 17, 2025, 1:28 PM EST - 8 months ago

Hologic: Reasonably, But Not Compellingly Valued

Jan 12, 2025, 4:00 PM EST - 8 months ago

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025

Jan 7, 2025, 4:04 PM EST - 8 months ago

Hologic to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:15 PM EST - 8 months ago

Hologic to Announce Financial Results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025

Jan 6, 2025, 8:05 AM EST - 8 months ago

Hologic Completes Acquisition of Gynesonics, Inc.

Jan 3, 2025, 12:06 PM EST - 9 months ago

Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz

ABT BMY LLY NVO UNH XBI XLV

Dec 18, 2024, 8:08 AM EST - 9 months ago

Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC

Dec 10, 2024, 4:01 PM EST - 9 months ago

Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines

Dec 9, 2024, 4:05 PM EST - 9 months ago

Martin Madaus Elected to Hologic Board of Directors

Dec 9, 2024, 8:05 AM EST - 9 months ago

New Data To Be Presented at SABCS 2024 Investigates the Potential Role of the Breast Cancer Index® Test in Identifying Patients With Minimal Risk of Distant Recurrence

Dec 2, 2024, 8:08 AM EST - 10 months ago

Hologic Presents New Research Demonstrating How Its Breast Imaging AI Solution Performs Similarly Across Diverse Populations

Nov 25, 2024, 8:22 AM EST - 10 months ago

Hologic Invites Attendees to Step Into the Future of Breast Health and AI at RSNA 2024

Nov 4, 2024, 7:26 PM EST - 11 months ago

Hologic, Inc. (HOLX) Q4 2024 Earnings Call Transcript

Nov 4, 2024, 4:01 PM EST - 11 months ago

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2024

Oct 19, 2024, 2:00 PM EDT - 11 months ago

Hologic to acquire Gynesonics in $350M deal to boost Fibroid treatments

Oct 14, 2024, 2:07 PM EDT - 11 months ago

Hologic Adds Gynesonics' Sonata System In $350M Acquisition To Boost Fibroid Treatments

Oct 14, 2024, 8:05 AM EDT - 11 months ago

Hologic to Acquire Gynesonics, Developer of Minimally Invasive Solutions for Women's Health

Oct 4, 2024, 8:22 AM EDT - 1 year ago

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2024 on Monday, November 4, 2024

Oct 1, 2024, 9:12 AM EDT - 1 year ago

Hologic CEO Steve MacMillan on breast cancer detection, future of AI-powered diagnostics

Sep 30, 2024, 9:17 AM EDT - 1 year ago

Hologic Unveils #BustTheMyth Campaign to Debunk Breast Cancer Myths and Empower Women This Breast Cancer Awareness Month

Aug 29, 2024, 8:08 AM EDT - 1 year ago

Hologic to Webcast Presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference

Jul 30, 2024, 12:50 PM EDT - 1 year ago

Hologic CEO on earnings beat: our Covid work has 'turbocharged' diagnostics business

ZacksResearch Sep. 10 at 3:09 PM

0 · Reply

ZacksResearch Sep. 10 at 2:09 PM

0 · Reply

Knot2 Sep. 5 at 8:18 PM

$KVUE $HOLX curtain being rolled back. $NVDA $QQQ $$OPEN

0 · Reply

StockAutoPro Sep. 5 at 7:50 PM

$HOLX: Buy target $64.55 Sell target $69.88 Expect potential growth in the medical technology sector due to increased healthcare demand.

0 · Reply

Knot2 Sep. 4 at 6:21 PM

$HOLX this company and its relationship with prior FDA… makes RFK look sane $QQQ $OPEN $NVDA

1 · Reply

ZacksResearch Sep. 4 at 2:10 PM

0 · Reply

ZacksResearch Sep. 4 at 12:42 PM

0 · Reply

StockAutoPro Sep. 4 at 5:03 AM

$HOLX: Buy target $64.24 Sell target $69.55 Significant growth in women's health segment suggests potential investment opportunity in this medical technology company.

0 · Reply

Knot2 Sep. 3 at 10:34 PM

$HOLX Is the Biozorb fiasco in the price of HOLX? 97% institutional holders Should be a RICO case Stuff that makes RFK look sane

0 · Reply

StockAutoPro Aug. 29 at 5:02 PM

$HOLX: Buy target $64.69 Sell target $70.02 Consider buying as company shows strong growth in medical imaging and diagnostics sector.

0 · Reply

ZacksResearch Aug. 29 at 12:24 PM

$HOLX: Positioned for growth or just holding steady? 🤔 Hologic's strategic acquisitions like Biotheranostics and Endomag are strengthening its portfolio, while the company's strong balance sheet supports more potential deals. Yet, the stock is down 7.7% YTD and carries a Zacks Rank #3 (Hold). Discover if HOLX has more room to run here 👉 https://www.zacks.com/stock/news/2744607/the-role-of-ma-in-hologics-growth-story-are-more-deals-in-sight?cid=sm-stocktwits-2-2744607-body-10165&ADID=SYND_STOCKTWITS_TWEET_2_2744607_BODY_10165

0 · Reply

ZacksResearch Aug. 29 at 11:24 AM

$HOLX growth strategy hinges on M&A — but will the deal flow continue? Strategic acquisitions have been a key driver of Hologic’s expansion, and the question now is whether more transactions are on the horizon. Full breakdown of the growth story here 👉 https://www.zacks.com/stock/news/2744607/the-role-of-ma-in-hologics-growth-story-are-more-deals-in-sight?cid=sm-stocktwits-2-2744607-teaser-10158&ADID=SYND_STOCKTWITS_TWEET_2_2744607_TEASER_10158

0 · Reply

SPYmyQQQ Aug. 28 at 6:33 PM

🚨 New Signal ✅ 💊 $HOLX 🗓️ Aug 28, 2025 🎯 Entry: $66.4700 🎯 Target: $79.1392 (+19.06%)

0 · Reply

BuffettBillionaire Aug. 27 at 7:27 AM

$HOLX tight consolidation, breakout watch in effect.

0 · Reply

ZacksResearch Aug. 25 at 1:57 PM

$BSX or $HOLX: Why BSX is Your Best Bet Right Now! 💪 📈 Boston Scientific's Cardiovascular & MedSurg momentum is impressive, with consensus estimates suggesting an 18.7% EPS improvement for 2025. 🔍 Strong acquisition strategy and favorable valuation make BSX a compelling opportunity versus HOLX. Discover the full analysis here 👉 https://www.zacks.com/stock/news/2741959/holx-vs-bsx-which-healthcare-stock-has-more-room-to-grow?cid=sm-stocktwits-2-2741959-body-9291&ADID=SYND_STOCKTWITS_TWEET_2_2741959_BODY_9291

0 · Reply

ZacksResearch Aug. 25 at 12:57 PM

$HOLX vs. $BSX — which one’s the real growth play? Both are in healthcare, but the race is about who’s got more room to run based on growth prospects. Full breakdown here 👉 https://www.zacks.com/stock/news/2741959/holx-vs-bsx-which-healthcare-stock-has-more-room-to-grow?cid=sm-stocktwits-2-2741959-teaser-9271&ADID=SYND_STOCKTWITS_TWEET_2_2741959_TEASER_9271

0 · Reply

StockAutoPro Aug. 25 at 12:03 AM

$HOLX: Buy target $66.26 Sell target $71.67 Expect upward momentum in medical technology stocks due to increased demand for diagnostic equipment.

0 · Reply

ZacksResearch Aug. 20 at 1:16 PM

Is $HOLX underappreciated in the cytology space? 💡 Despite a 5.2% gain over six months, Hologic is trading at a forward P/E of 15.23X, well below the industry average of 28.67X. Its Genius digital cytology system is poised to drive future growth, especially as it addresses labor shortages and infrastructure limitations globally. Discover if HOLX is a hidden gem in healthcare 👉 https://www.zacks.com/stock/news/2739809/whats-behind-hologics-positive-long-term-outlook-for-cytology-unit?cid=sm-stocktwits-2-2739809-body-8547&ADID=SYND_STOCKTWITS_TWEET_2_2739809_BODY_8547

0 · Reply

ZacksResearch Aug. 20 at 12:16 PM

$HOLX long-term bull case? 👀 The company’s Cytology unit is showing a positive outlook, pointing to sustained strength ahead. See the full breakdown of what’s driving the optimism 👉 https://www.zacks.com/stock/news/2739809/whats-behind-hologics-positive-long-term-outlook-for-cytology-unit?cid=sm-stocktwits-2-2739809-teaser-8524&ADID=SYND_STOCKTWITS_TWEET_2_2739809_TEASER_8524

0 · Reply

ZacksResearch Aug. 13 at 12:51 PM

$HOLX poised for growth — is it time to hold? 🚀 Hologic's Breast Health division is showing sequential improvement, with 3D gantry shipments up compared to the prior quarter and new leadership driving sales focus. Plus, HOLX trades at a forward P/E of 15.28X, well below the industry average of 28.00X. See why HOLX could be a promising investment 👉 https://www.zacks.com/stock/news/2706735/hologic-eyes-organic-growth-rebound-in-2026-on-breast-health-strength?cid=sm-stocktwits-2-2706735-body-7573&ADID=SYND_STOCKTWITS_TWEET_2_2706735_BODY_7573

0 · Reply

ZacksResearch Aug. 13 at 11:51 AM

$HOLX targeting a growth comeback in 2026 📈 The company sees a rebound in organic growth driven by strong performance in Breast Health. Full outlook here 👉 https://www.zacks.com/stock/news/2706735/hologic-eyes-organic-growth-rebound-in-2026-on-breast-health-strength?cid=sm-stocktwits-2-2706735-teaser-7562&ADID=SYND_STOCKTWITS_TWEET_2_2706735_TEASER_7562

0 · Reply

ZacksResearch Aug. 8 at 1:20 PM

$HOLX: Diagnostics unit faces headwinds, but growth drivers remain strong! 🚀 Despite geopolitical challenges, the Diagnostics segment posted just 0.9% YoY growth, with support from BV, CV/TV assays, and Panther Fusion. Innovative strides with Biotheranostics in oncology add to future potential. Discover the full analysis here 👉 https://www.zacks.com/stock/news/2683571/hologics-diagnostics-arm-set-for-long-term-upside-whats-behind-it?cid=sm-stocktwits-2-2683571-body-6826&ADID=SYND_STOCKTWITS_TWEET_2_2683571_BODY_6826

0 · Reply

Market Cap	14.76B
Revenue (ttm)	4.03B
Net Income (ttm)	789.50M
EPS (ttm)	N/A
PE Ratio	15.78
Forward PE	15.45
Profit Margin	19.59%
Debt to Equity Ratio	0.52

Volume	1,005,400
Avg Vol	1,667,348
Day's Range	N/A - N/A
Shares Out	222.42M
Stochastic %K	2%
Beta	0.57
Analysts	Sell
Price Target	$74.38